# Efficacy/Safety of Amlodipine Plus Losartan Versus Amlodipine in Patients With Essential Hypertension

> **NCT00940667** · PHASE3 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 185 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Amlodipine plus Losartan
- **DRUG:** Amlodipine

## Key facts

- **NCT ID:** NCT00940667
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 185 (ACTUAL)
- **Last updated:** 2016-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00940667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00940667, "Efficacy/Safety of Amlodipine Plus Losartan Versus Amlodipine in Patients With Essential Hypertension". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00940667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*